Whether your family is affected by Alzheimer's or you simply want to learn more about the disease, this conference in Boca ...

Targeted therapies, guided by molecular testing, offer significant benefits, including fewer side effects and personalization ...

INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials ...

BioLife Solutions ( ($BLFS) ) has issued an update. On November 17, 2025, BioLife Solutions released an investor presentation highlighting its ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has opined that the drug ...

The latest update is out from Purple Biotech ( (PPBT) ).

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO, Nov. 21, 2025 (GLOBE NEWSWIRE ...

Internal records reveal that for years Penn State’s clinical cancer research was mired in deep-rooted and potentially ...

Continued treatment: On Tuesday, Dec. 2, at 5:05 PM PT and Wednesday, Dec. 3, at 2:40 PM PT, new analyses will be presented on benefits of continued therapy and estimated time savings over 10 years of ...

The posters presented at SITC 2025 feature trial designs for the Phase 2 and Phase 3 studies in advanced NSCLC patients receiving ateganosine followed by a checkpoint inhibitor, cemiplimab (Libtayo®).

Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM ESTCompany ParticipantsJan van de Winkel - Co-Founder, ...